JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Most Cited Paper
in Immune Cell Function and Interaction
18 Months Post-Publication
Class of 2026
“JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immune-cell-function-and-interaction/2026/
Topics
JAK inhibition · Immune checkpoint blockade · Hodgkin lymphoma · ruxolitinib · PD-1/PD-L1 blockade · nivolumab · JAK-STAT pathway · Immunotherapy resistance · neutrophil-to-lymphocyte ratio · Myeloid-derived suppressor cells · T cell exhaustion · immunostimulatory myeloid cells · T cell division · cytokine-producing T cells · relapsed or refractory Hodgkin lymphoma
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immune Cell Function and Interaction Papers, Class of 2026. https://pri.pepkio.com/top-papers/immune-cell-function-and-interaction/2026. Accessed 2026-07-15. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459